The mergers and acquisitions (M&A) decision-making process is highly complex in the life science industry. Challenges we face in the M&A space include the rapid evolution of technological innovation, competition from emerging companies, and the meshwork of intellectual property. History demonstrates that only a small fraction of M&A deals will actually create long-term value for shareholders.
Life Science companies are obliged to be very selective when considering M&A activities, being certain of the added value to be gained.
- In: What We Do
- Hits: 2495
Patents are commonly seen as the most important intellectual property (“IP”) right for life science companies. A patent for an invention is the grant of a property right to the inventor. This ‘right to exclude others has traditionally been used by life science companies to erect a significant barrier of entry to its competitors into the marketplace.
- In: What We Do
- Hits: 1802
ImmuneVax adheres to the continuous use of best practices in project management in the pharmaceutical, biotechnology, medical device and diagnostics industries.
Our solid knowledge of project management processes and methodology is critical to accentuating your preclinical project success.
At the outset, we gain a detailed understanding of your preclinical development process needs.
- In: What We Do
- Hits: 3804
The benefits of having a well-constructed Regulatory Affairs roadmap are innumerable. At ImmuneVax, we realize the value added that stands to be derived by having a rational Regulatory Affairs plan at the outset to support the enhanced passage of products to market.
ImmuneVax's main Regulatory Affairs focus is on Title 21 of the Code of Federal Regulations that governs food and drugs within the United States for the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and the Office of National Drug Control Policy (ONDCP).
- In: What We Do
- Hits: 2018
The goal of a company is to develop and sell products that will generate enough profit to justify the effect and capital that goes into building the company. Science and technology are a means to an end. Therefore, to be entrepreneurs, scientists must learn to put business ahead of science when developing a commercial strategy. Pharmaceutical drug development demands more attention and capital and offers the greatest potential rewards of any products in the biotechnology sector.
- In: What We Do
- Hits: 2597
Life science companies can strategically use their intellectual property assets to generate revenue in a number of different ways including licensing their IP and developing joint ventures and strategic alliances. Venture capitalists place a high value on strategic alliances and joint ventures as they provide an opportunity to demonstrate the validity of the science and its commercial potential.
In the recent past, biopharmaceutical and other life science companies have faced some formidable challenges.
- In: What We Do
- Hits: 4040
Strategy is the point from which your business creates, executes, innovates, and thrives. However, a strategy isn’t worth anything if you can’t execute it. Ensure that your business is positioned for success by building a strong strategic foundation. ImmuneVax strategizes with a focus on action. Our goal is to provide you with a comprehensive roadmap that leads direct to success.
- In: What We Do
- Hits: 1827
At ImmuneVax, our Technology Transfer Team (TTT) helps move technologies from the Lab to the marketplace to benefit society and the global economy by developing and managing an array of partnerships with the private sector. TTT negotiates and effects licenses to a wide range of cutting-edge technologies, both to and from companies.
- In: What We Do
- Hits: 2041
ImmuneVax specializes in technology transfer out of universities and other academic institutions. University technology transfer expertise and commercialization have not kept pace with the increase and breadth of research funding in recent years. More than 50 percent of the revenues from licenses in the life sciences is now clustered in just ten universities and is associated with a very small number of commercial products and services.
ImmuneVax is well aware of the common barriers to commercialization in the life sciences, and over the years, has refined its strategies to overcome those barriers.
- In: What We Do
- Hits: 2508
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque posuere mi id ante ultricies sit amet adipiscing lectus tincidunt. Morbi tortor libero, fringilla id pharetra at, sollicitudin id nibh. Maecenas in ullamcorper lectus. Fusce tristique condimentum eleifend. Fusce pellentesque risus eu tortor feugiat dignissim bibendum leo tempus. Sed sedrisus non dolor commodo commodo vitae sed ante.
- In: What We Do
- Hits: 3162
